Covered, but the lab market is working against it. A 6.69% yield on a $0.72 quarterly dividend is covered by adjusted FFO — $1.73 per share in Q2 2026 against the $0.72 dividend, about a 42% payout. But the dividend was cut 45% in December 2025 from $1.32, same-property NOI fell 10.6% in Q2 as occupancy slipped to 86.9% from 92.6% a year earlier, and net debt and preferred stock stood at 7.0× annualized adjusted EBITDA. The payout is safe on paper; the business behind it is shrinking.
Key risk: Life-science leasing staying weak — further occupancy loss, delayed dispositions, or another round of impairments would keep leverage near 7.0× and put the rebased dividend back under pressure.
Changes if: Occupancy recovers toward 90% and leverage falls toward the 5.6×–6.2× year-end target, or same-property NOI turns positive. Until then the verdict stays cautious.
- ✓FFO coverage check: Adjusted FFO of $1.73 per share in Q2 2026 covers the $0.72 dividend — about 42% paid out. Coverage is not the problem.
- !Yield check: 6.69% indicated — $0.72/qtr × 4 at the $43.08 close on Oct. 23, 2026. The high yield mostly reflects a share price that fell with the dividend cut, not generosity.
- !Balance-sheet check: Net debt and preferred stock of 7.0× annualized adjusted EBITDA at June 30, 2026, with $222.5 million of Q2 real-estate impairments; $3.6 billion of liquidity buys time, not a turnaround.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.